Source: Annual Congress 2007 - Towards controlling severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Sears, A. Ottosson, F. Radner, S. Suissa (Hamilton, ON, Montreal, QC, Canada; Lund, Sweden). Safety of formoterol in asthma trials. Eur Respir J 2007; 30: Suppl. 51, 1586

Member's Comments

No comment yet.

Related content which might interest you: Safety of formoterol in asthma clinical trials Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Safety of formoterol in asthma clinical trials: an update Source: Eur Respir J 2014; 43: 103-114 Year: 2004 Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Efficacy and tolerability of formoterol Turbuhaler in 6–11 year old children with asthma, not adequately controlled with inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002 Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 Safety of formoterol in children and adolescents: experience from asthma clinical trials Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Safety of formoterol by Turbuhaler(R) as reliever medication compared with terbutaline in moderate asthma Source: Eur Respir J 2002; 20: 859-866 Year: 2002 Efficacy of once-daily tiotropium Respimat in adults with asthma based on GINA Steps 2–5 Source: International Congress 2017 – Bronchial asthma management Year: 2017 Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials Source: Eur Respir J 2009; 33: 21-32 Year: 2009 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Long-term safety of inhaled formoterol in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Long-term safety of inhaled formoterol in adult asthma patients Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015